



STRASSENBURGH

PRESCRIPTION PRODUCTS

785 JEFFERSON ROAD, BOSTON, MASSACHUSETTS 02118, U.S.A. 617-556-1756, BOSTON 11, U.S.A. 617-556-1756

(716) 231-1017

February 5, 1971

ALL FIELD SALES PERSONNEL

You are aware of the August Sub ruling by the Food and Drug Administration in which Bupropion[®], Jonamin[®], and Biphentamine-TO were ruled as "possibly effective". As a result of this ruling we had to submit, within six months, efficacy and certain other data. Our program to successfully achieve these objectives was:

1. to search out the best clinicians in the United States to conduct the clinical studies
2. to prepare protocols and laboratory criteria which far exceeded FDA demands
3. to consult with the FDA for the purpose of keeping them continually apprised of our progress and when possible their recognition of the quality of the work that was being done

The program is progressing satisfactorily and due to the excellence of the work that is being done, the FDA has today granted us a six month extension of the time period in which to submit the data. This represents the recognition of high quality of the work which is being done by our laboratories and clinicians by the FDA and also establishes that the FDA's intent is to accurately establish the therapeutic value of these agents. The extension of time given by the FDA was not an extension of the deadline to all manufacturers concerned but specifically to Strassenburgh.

This information is supplied to you so you will know the status of Bupropion[®], Jonamin[®], and Biphentamine-TO as of February 8, 1971 and should not be used in any way in the promotion of these products.

Cordially yours,

 A handwritten signature in dark ink, appearing to read "Isaac R. McGraw, II".

Isaac R. McGraw, II
Vice President

IRG/sw